NCT05509855

A Long-Term Safety Follow-Up Study for Patients Treated With Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007)

Study Summary

This study will provide long-term follow-up for patients who have received treatment with WU-CART-007 in a previous clinical trial. In this study, patients will be followed for up to 15 years after their last dose of WU-CART-007 for evaluation of delayed adverse events, presence of persisting WU-CART-007 vector sequences, and overall survival and progression-free survival.

Want to learn more about this trial?

Request More Info

Interventions

Genetic: WU-CART-007GENETIC
No study drug is administered in this study. Patients who have received WU-CART-007 will be enrolled in this study for Long Term Safety and Efficacy

Study Locations

FacilityCityStateCountry
City of HopeDuarteCaliforniaUnited States
Childrens Hospital LALos AngelesCaliforniaUnited States
Washington UniversitySt LouisMissouriUnited States
Children's Hospital of PhiladelphiaPhiladelphiaPennsylvaniaUnited States
Peter MacCullam Cancer CenterMelbourneAustralia

Official Trial Information

View on ClinicalTrials.gov

Data sourced from ClinicalTrials.gov. Last updated: April 14, 2026